viral infection at oral

1. CYTOMEGALOVIRUS
Presented by
Erna Sung, drg
1

2. DEFINITION
Cytomegalovirus (CMV) 
infection herpes virus.
Swollen lymph glands, fever &
fatigue
Asymptomatic (Sieve, 2014)
2

3. EPIDEMIOLOGY
60-80%  developed country
80-100%  developing country
Depends on geography, ethnic,
sosio-economy
3

4. ETIOLOGY
Cytomegalovirus/HHV-5
4

5. PREDISPOSING FACTORS
Contact with CMV infected patient
Transmission  saliva, blood,
sexual,transplacenta, transplantation.
saliva, urine, semen or body fluids after
incubation period 20-40 days
Immunocompromised patient  severe &/
long-term or reactivation 5

6. PATOGENESIS
CMV  epithelium lining the
respiratory, GI or genitourinary tract.
Direct route  transfusion of blood
& blood products, transplantation
 Latency  myeloid progenitor cells
& endothelium cells solid organ
6

7. DIAGNOSIS
Salivary gland  acute sialadenitis
 painful, xerostomia
Mucosal ulceration  AIDS
Gingival infection & hyperplasia
Dental significance 7

8. FIG 1. GINGIVAL INFECTION AND ULCERATION SEEN IN THE
PATIENT WITH CYTOMEGALOVIRUS INFECTION.
8

9. LABORATORY STUDIES
Antigen testing
Qualitative PCR
Quantitative PCR
Shell vial assay
Cytopathology
Imaging studies 9

10. DIFFERENTIAL DIAGNOSIS
EBV
HHV-6
HIV
Toxoplasmosis
10

11. TREATMENT
Prevention  Hyperimmune
gamma globulin
Symptomatic
Antiviral therapy  ganciclovir,
Valaciclovir, valganclovir
11

12. PROGNOSIS
Depens on severe infection and
person’s who have it.
12

13. THANK YOU
13

14. RUBEOLA/MEASLES AND MUMPS
PRESENTED BY : TONI MASRURI, drg
7/15/2022
14

15. DEFINITION
 Rubeola is a viral infection
and very contagious (easily spread)
infection that causes a rash all over
your body. It is also called rubeola
or red measles
 Isn’t same with rubella
 Others name : measles, morbili
 Mumps is a viral infection
transmitted by and affecting only
humans.
 While the salivary glands
(especially the parotid gland) are
well known to be involved during a
mumps infection  swelling
 Others name : parotitis epidemica
7/15/2022
15
RUBEOLA MUMPS

16. EPIDEMIOLOGY
 Rubeola is occurs throughout
the world
 High on spring/winter season
 Often  child< 15 y, young
adult
 Crowded people  high
 Spread all the world
 often  child < 15 y
 Others name : parotitis
epidemica
 People consumption tiroid
supresor  high risk
7/15/2022
16
RUBEOLA MUMPS

17. ETIOLOGY
 PARAMYXOVIRUS, GENUS
MORBILIVIRUS
 PARAMYXOVIRUS, GENUS
RUBULAVIRUS
7/15/2022
17
RUBEOLA MUMPS

18. PATHOGENESIS RUBEOLA
7/15/2022
18

19. PATHOGENESIS MUMPS
7/15/2022
19

20. CLINICAL FEATURES RUBEOLA
 Prodrome
 Stepwise increase in fever to
380c or higher
 Cough, coryza, conjunctivitis
 Koplik spots
7/15/2022
20
RUBEOLA

21. CLINICAL FEATURES RUBEOLA
 Rash
 2-4 days after prodrome, 14
days after exposure
 Persists 5-6 days
 Begins on face and head
 Maculopapular all over body
7/15/2022
21
RUBEOLA

22. CLINICAL FEATURES MUMPS
 FEVER 38,5-40 0C
 HEADACHE
 MIALGIA
 ANOREKSIA
 PAIN OPEN/CLOSE MOUTH
 SWELLING PAROTHYDE GLAND
7/15/2022
22
MUMPS

23. DIFFERENTIAL DIAGNOSIS
 RUBELLA (GERMAN MEASLES)
 RASH AFTER TAKE MEDICINE
 SCARLET FEVER
 RICKETSIA  PAROTITIS OTHER CAUSA:
 HIV
 INFLUENZA
 CITOMEGALOVIRUS
 PARAINFLUENZA

7/15/2022
23
RUBEOLA MUMPS

24. COMPLICATION
 DIARRHEA
 EAR INFECTION
 PNEUMONIA
 BLINDNESS
 ENCEPHALITIS
 MENINGITIS
 ENCEPHALITIS
 ORCHITIS
7/15/2022
24
RUBEOLA MUMPS

25. TREATMENT AND PREVENT
 SUPORTIF LIQUID/INFUSE,
ANTIPIRETIK
 VIT A HIGH DOSE
 PREVENT VACCINATION
MMR
 DIET HCHP
 ANALGETIK
 COMPRESS  HOT AND COOL
7/15/2022
25
RUBEOLA MUMPS

26. PROGNOSIS
 2.2 FROM 1000 DIE  SELF LIMITING DISEASE
7/15/2022
26
RUBEOLA MUMPS

27. 7/15/2022
27